Abstract: Methods, techniques, and kits are provided herein for purifying cells using molecular targeting, at a cellular or subcellular level. The techniques comprise labeling a biological sample comprising cells with a probe capable of producing a protective barrier. The barrier is deposited onto the surface of the labeled cells or structures, to protect and retain the biological material under the barrier. A micropurification solution is applied to the biological sample, wherein the micropurification solution degrades, digests, or otherwise processes cells not covered by the barrier, allowing isolation of the target cells. In some aspects, a plurality of probes, each specific to a different target, may be used. The techniques may be performed without the need for complex instrumentation involving microscopy.

Abstract: Detection of under-expression of selected genes in NK cells is used to confirm a hypoxic tumor microenvironment that is ordinarily suppressive with respect to ADCC and cytotoxic cell killing of NK cells. Most notably, while hypoxia is known to upregulate HIF-1? and genes under the control of HIF-1?, hypoxia in a tumor microenvironment led to under-expression of selected genes, including HIF-1?. Thus, gene expression analysis of certain genes on NK cells can be used to detect conditions in a tumor that would indicate use of haNK cells.

Abstract: A method is provided to measure modulation of bile salt export transport and/or formation activity in hepatocyte or stable cell line preparations by test agents including but not limited to drugs, drug candidates, biologicals, food components, herb or plant components, proteins, peptides, DNA, RNA. Furthermore, the method is to determine modulation of bile salt export transport and/or formation activity not only by said test agents, but further their metabolites or biotransformed products formed in situ. The bile salt export transport and/or formation activity modulation includes but not limited to inhibition, induction, activation and/or regulation. The method can be practiced to identify test agents, which have potential to cause liver injury, drug-drug interactions, and/or can be used as therapeutic agents for the treatment of cholestasis, abnormality of bile salt metabolism, liver diseases and cholesterol abnormality.

Abstract: The invention relates to biomarkers and uses thereof, in particular to a set of proteins or mRNAs that provides a significant indication as to whether a cell is senescent or not. Provided is the use of a biomarker panel comprising six or more polypeptides, or their encoding mRNA's, wherein the panel comprises at least the biomarkers TSPAN13, GDNF, C2CD5, SUSD6, BCL2L2, PLK3, or a variant or fragment thereof, as a biomarker set for cellular senescence. Also provided is a senescent cell detection kit for detecting senescent cells, and a drug conjugate for killing a senescent cell.

Abstract: The present disclosure is directed relates to assays, including but not limited to, leukocyte adhesive function assays (LAFA), devices and/or methods of using such assays. Disclosed embodiments may be used in diagnostic, analytic and/or prognostic applications. Certain embodiments are also related to stratifying, predicting and/or determining how one or more subjects are likely to respond and/or is responding to a drug. The present disclosure also relates to one or more methods of optimising a dosage regimen for one or more subjects taking a drug. In addition, the present disclosure is also related to minimise or potentially reduce drug side effects.

Abstract: Certain embodiments provide a marker for detecting a detection target substance, including an assay reagent having a medium, and a composition containing a solvent or a solvent mixture, and a fluorescent coagulation factor that has a fluorescence property that changes as it coagulates in presence of the detection target substance. A difference of a hydrophobicity parameter LogP between the solvent and a part or the entirety of the detection target substance is equal to or smaller than 1.53.

Abstract: The present invention relates to methods and kits for detecting a fusion mRNA transcript or polypeptide encoded by the fusion mRNA transcript. The method includes obtaining a biological sample from a subject and providing one or more reagents capable of binding a fusion mRNA transcript or polypeptide encoded by the fusion mRNA transcript, wherein the fusion mRNA transcript or polypeptide encoded by the fusion mRNA transcript comprises the 3? end of ex on 25 of INPP5D fused to the 5? end of ex on 2 of ATG16L1 or the polypeptide encoded by the 3? end of ex on 25 of INPP5D fused to the 5? end of ex on 2 of ATG16L1, respectively.

Abstract: A method of diagnosing and treating insulin resistance at the end of a first phase insulin response to glucose in a mammalian subject is disclosed. The method includes administering an amount of glucose to the mammalian subject capable of producing a first phase insulin response to glucose. At the end of the first phase insulin response to glucose, a serum sample is obtained from the mammalian subject, from which the levels of at least one biomarker for insulin resistance may be measured, from a group including insulin, proinsulin, C-peptide, glucose, and hemoglobin A1c. An analysis of the levels of the biomarkers in the serum samples may be performed to determine if the mammalian subject is insulin dependent. If the mammalian subject is determined to have insulin resistance, treatments for insulin resistance may be prescribed. Prescribed treatments include weight loss, dietary modification, exercise, or drug therapy.

Abstract: THE present application relates to a method of detecting one or more analytes in a sample, the method comprising (a) providing a carrier nucleic acid molecule with at least one single-stranded region; (b) providing one or more aptamers specific for the analyte, wherein the aptamers additionally comprise a single-stranded portion complementary to at least one single-stranded region on the carrier nucleic acid; (c) contacting the carrier nucleic acid and one or more aptamers with the sample, forming a carrier nucleic acid/N aptamer/analyte complex, and; (d) detecting the presence of the carrier nucleic acid/aptamer/analyte complex.

Abstract: Provided are methods of detecting and quantitatively measuring protein-protein interactions between proteins present on the surface of different cells using a sensitive antibody-based assay. Antibodies specific for each target protein are either directly labeled, or are detected by labeled secondary antibodies. The antibodies are labeled with detectable tags that are releasable when the target proteins are within proximity to each other. Also provided are methods for facilitating diagnosis, prognosis, and treatment of cancer using this assay to detect protein-protein interactions between target proteins of interest. Methods of screening test agents that impact the protein-protein interaction are also provided.

Abstract: The present invention relates to methods of identifying an epitope on a protein that can be bound by an antibody. Methods of the invention typically involve a step of limited or restricted proteolysis of a protein using a single first protease or a combination of first proteases, and a further proteolysis step using a single second protease or combination of second proteases. The invention also relates to identified epitopes and to antibodies which bind to epitopes that have been identified by methods of the invention.

Abstract: The present disclosure relates to a method for detecting a compound, comprising the steps of: contacting a compound with a solid analytical surface (SAS), thereby forming an SAS with an absorbed compound; contacting the SAS with the absorbed compound with a mass tag, wherein the mass tag reacts with the absorbed compound, thereby forming an SAS with a covalently mass-tagged absorbed compound; and detecting the covalently mass-tagged absorbed compound by mass spectrometry. Also disclosed is a device for collecting breath aerosol, comprising a card or an envelope, wherein the card or the envelope comprise a tab, wherein the tab is a SAS.

Abstract: Microfluidic devices for use with reagents bound to microspheres for determination of the concentration of an analyte in a liquid sample are provided. The devices include two sequential mixing channels that promote rapid binding of microsphere-bound reagents with reagents in solution and a means for detecting labeled microsphere-bound reaction products. Also provided are methods for using the devices with microsphere-bound reagents to determine the concentration of an analyte in a liquid sample and to measure the binding affinity of antibody for an antigen.

Abstract: The present disclosure relates to magnetic particles, wherein each particle has a polymer matrix and at least one magnetic core (M), wherein the polymer matrix has at least one crosslinked polymer and wherein the magnetic particle has a particle size in the range of from 1 to 60 micrometer. Further, the present disclosure relates to a method of preparing such particles, and to particles obtainable or obtained by said method. Moreover, the present disclosure uses these magnetic particles for qualitative and/or quantitative determination of at least one analyte in a fluid. Further, the present disclosure relates to a method for determining at least one analyte in a fluid sample using the contacting of a magnetic particle of the disclosure or a magnetic particle obtained by the method of the present disclosure with a fluid sample having or suspected to have the at least one analyte.

Abstract: A method and system for interaction analysis are disclosed. An example method for evaluation of an interaction between an analyte in a fluid sample and a ligand immobilized on a sensor surface of a biosensor includes providing a reference binding curve, representing a reference interaction for a predetermined acquisition cycle, by acquiring, using the biosensor, one or more binding curves for a reference-analyte ligand interaction at the predetermined acquisition conditions, acquiring, using the biosensor, a sample binding curve for the analyte ligand interaction for the predetermined acquisition cycle including at least one association phase wherein the sensor surface is put into contact with a fluid sample including analyte at a predetermined concentration, and generating a graphical user interface, including an upper threshold curve and a lower threshold curve defined with respect to the reference binding curve.

Abstract: The invention provides a method for determining a systemic lupus erythematosus-associated disease state in a subject comprising the steps of (a) providing a sample to be tested; and (b) measuring the presence and/or amount in the test sample of one or more biomarker(s) selected from the group defined in Table A, wherein the presence and/or amount in the test sample of the one or more biomarker(s) selected from the group defined in Table A is indicative of a systemic Lupus-associated disease state. The invention also provides an array and a kit suitable for use in the methods of the invention.

Abstract: This document provides methods and materials for detecting PCA-2-specific autoantibodies, which can be associated with paraneoplastic neurological disorders and cancers associated with PCA-2-specific autoantibodies.

Abstract: Provided is a kit for asthma diagnosis comprising a strip including a base part, a first reaction part formed on the base part, and a developing membrane formed between the first reaction part and the base part, in which the first reaction part includes a monoclonal antibody expressed from a hybridoma cell line of Accession Number KCLRF-BP-00389 (Accession Date: Jan. 9, 2017, Accession Institute: Korea Cell Line Research Foundation (KCLRF)) and the second reaction part includes a monoclonal antibody expressed from a hybridoma cell line of Accession Number KCLRF-BP-00389 (Accession Date: Jan. 9, 2017, Accession Institute: Korea Cell Line Research Foundation (KCLRF)).

Abstract: The technology described in this document can be embodied in a test strip for use in measuring a level of an ST2 cardiac biomarker in a whole blood sample. The test strip includes a base, and a plurality of conjugates, wherein each conjugate includes a reporter group bound to a first antibody that binds to ST2. A conjugate pad holds the plurality of conjugates that bind with ST2 to produce conjugate-ST2 complexes. The test strip also includes a plurality of second antibodies that bind to ST2, and a plurality of third antibodies that bind to the conjugate-ST2 complexes. The plurality of second antibodies are bound to a membrane in a test location, and the plurality of third antibodies are bound to the membrane in a control location. A plasma separation pad passes blood plasma from a whole blood sample to the conjugate pad while inhibiting other components.

Abstract: An implantable diagnostic device in accordance with the present disclosure provides various benefits such as a compact size thereby allowing implanting of the device inside animate objects; low cost due to incorporation of inexpensive detection circuitry and the use of conventional IC fabrication techniques; re-usability by heating thereby allowing multiple diagnostic tests to be performed without discarding the device; and a configuration that allows performing of simultaneous and/or sequential diagnostic tests for detecting one or more similar or dissimilar target molecules concurrently or at different times.

Abstract: A method of diagnosing or monitoring Mycobacterium avium subspecies paratuberculosis (MAP) infection, which method comprises detecting the presence of the polypeptide (MAP P900) encoded by the positive strand of IS900, or a fragment thereof, in a sample from a subject, wherein MAP P900, or a fragment thereof, is detected using an antibody, or an antigen-binding fragment thereof, that binds to MAP P900.

Abstract: A method of determining colorectal cancer status in an individual, which comprises abundance profiling of the individual's microbiome.

Abstract: In an effector type regulatory T cell detecting method using flow cytometry, a control sample containing a CD4-positive T cell population is measured, and based on a result of measuring the control sample, a FOXP3 level as a division reference for dividing a FOXP3-positive T cell population contained in the CD4-positive T cell population at a predetermined ratio is acquired as a reference value to be used for measuring a biological sample. A biological sample containing a CD4-positive T cell population is measured, and based on a result of measuring the biological sample, effector type regulatory T cells are detected from a cell population having a FOXP3 level higher than the reference value.

Abstract: Disclosed herein are methods for producing genetically modified cells expressing HLA-G (e.g., cell surface HLA-G) persistently, and nucleic acid compositions useful for generating such genetically modified cells. Also disclosed are cell therapy methods that utilize genetically modified cells that express HLA-G persistently. The HLA-G genetic modifications described herein provide the cells with characteristics of reduced immunogenicity and/or improved immunosuppression, such that these cells have the promise of being universal or improved donor cells for transplants, cellular and tissue regeneration or reconstruction, and other therapies.

Abstract: The invention relates to a method for detecting, by means of flow cytometry, the presence of normal plasma cells and tumoral plasma cells in a sample of cells from a patient.

Abstract: A method for diagnosing cancer in an expanded biological tissue sample of a patient comprising providing at least one sample image of the expanded biological tissue sample; providing a computer configured to analyze the sample; analyzing, with the computer, the sample detect and segment nuclei; calculating, with the computer, molecular characteristics of those nuclei; and determining, with the computer, a diagnosis of cancer of the sample by comparing the sample with a benign normal tissue reference.

Abstract: The present invention provides methods for screening and diagnosing prostate cancer based on a correlation between cancer cell growth, cancer lethality or recurrence and the expression level of ZFP36 or NEDD9 and PTEN in conjunction with ZFP36. The disclosure also provides methods for screening and diagnosing prostate cancer based on a correlation between cancer lethality and the genotype of rs1910301 SNP. Also provided are methods for treating prostate cancer comprising providing a treatment or monitoring based on the expression level of ZFP36, the expression level of NEDD9, and the expression level of ZFP36 in conjunction with PTEN levels or the genotype of rs1910301 SNP.

Abstract: The present invention provides new compositions and methods for treating prostate cancer, e.g., drug-resistant prostate cancer, such as anti-androgen drug (e.g., enzalutamide) resistant and/or castration resistant prostate cancer (CRPC). These new compositions include, but are not limited to, pharmaceutical compositions that include an AR-V7 inhibitor, such as niclosamide. Alternatively, these new compositions can include, but are not limited to, pharmaceutical compositions that include an AKR1C3 inhibitor, such as indomethacin. These new methods include, but are not limited to, methods of administering an AR-V7 inhibitor, such as niclosamide, and/or an AKR1C3 inhibitor, such as indomethacin, to treat patients having prostate cancer. The present invention also provides methods of inhibiting androgen receptor variant expression, e.g. AR-V7, and methods of killing cells expressing AR-V7.

Abstract: The present invention provides methods of testing anti-STn antibodies for their ability target cancer stem cells by isolating cancer stem cells from cultures, contacting them with anti-STn antibodies being tested, and measuring resulting cell viability.

Abstract: Provided herein are lipid vesicle-coated magnetic beads, and methods of making and using the same.

Abstract: The present invention relates to an in vitro method for the prognosis of the survival time of a patient suffering from a solid cancer, comprising the quantification of the cell density of follicular B cells present in tumor-induced lymphoid structures from said patient, wherein a high density of follicular B cells indicates that the patient has a favorable prognosis and a low density of follicular B cells indicates that the patient has a poor prognosis.

Abstract: Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.

Abstract: The present invention provides a novel approach to cancer diagnosis and therapy of cancer by providing compositions and methods for the identification and specific targeting of the cancer stem cell populations present in a tumour to eradicate, or slow or prevent tumour (5) growth and spread, including the potential for tumour metastasis, by modulation of the Renin-Angiotensin System including, but not limited to, Renin Receptor, Angiotensin II Receptor (2) and a secreted form of the Renin Receptor.

Abstract: The present invention provides methods, devices, and kits to improve procedures for reducing carbohydrates, such as glycans released from glycoconjugates, or for labeling carbohydrates by reductive amination.

Abstract: The present invention relates to diagnostic markers of fertility, reproductive dysfunction and infertility management. In particular, the invention relates a method for predicting the fertility potential of a subject, the method comprising determining the level of one or more of GDF9, BMP15 and/or cumulin in the subject.

Abstract: Methods for producing isotopically-labelled peptides are provided. Aspects of the method include: contacting a sample including a metabolically tagged protein with a cleavable probe to produce a probe-protein conjugate; separating the probe-protein conjugate from the sample; digesting the probe-protein conjugate to produce a probe-peptide conjugate; and cleaving a cleavable linker to release an isotopically labelled peptide. The method may further include: identifying a predetermined isotopic pattern in a mass spectrum; determining an amino acid sequence of the isotopically labelled peptide; and identifying the site of protein glycosylation based on the determined amino acid sequence. Also provided are cleavable probes for practicing the subject methods, described by the Formula: A-L-(M-Z) where A is an affinity tag, L is a cleavable linker, M is an isotopic label and Z is a chemoselective tag capable of cross-linking a metabolically tagged protein.

Abstract: The present invention relates to methods of diagnosing a liver disorder in a patient, as well as methods of monitoring the progression of a liver disorder and/or methods of monitoring a treatment protocol of a therapeutic agent or regimen. The invention also relates to assay kits used in connection with the diagnostic methods described herein.

Abstract: Disclosed herein are antibodies having binding specificity to the amino acid sequences Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) and Thr Val Glu Val Asp (SEQ ID NO:14), and methods of detecting cell death in a sample, comprising contacting the sample with a first antibody specific for a C-terminal amino acid sequence Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) or Thr Val Glu Val Asp (SEQ ID NO:14) of a CK18 protein fragment having a C-terminal amino acid sequence of Val Glu Val Asp (SEQ ID NO:2) and a second antibody that specifically binds an epitope that is present in both full-length CK18 and the CK18 protein fragment, and that does not overlap with SEQ ID NO:1 or SEQ ID NO:14, under conditions such that the CK18 protein fragment present in the sample specifically binds to the first antibody and the second antibody, wherein one of the antibodies is bound to a solid support and the other antibody is bound to a detection moiety capable of producing a signal; optionally removing any unbo

Abstract: The present disclosure is generally related to neurofibromatosis type 1. More particularly, disclosed herein are methods for detecting behavioral disorders, methods for detecting cognitive impairment, and methods for detecting brain neurofibromin-dependent dopaminergic signaling associated with neurofibromatosis type 1.

Abstract: The present invention relates to diagnostic methods, reagents, and kits for detecting and diagnosing Early Stage Parkinson's disease.

Abstract: A method comprises obtaining temporal measurements associated with a heterogeneous material; building a numerical model of a material by assigning initial approximations to the temporal measurements; modifying the numerical model to create a modified numerical model; generating simulated temporal measurements associated with the temporal measurements using the modified numerical model; determining a reward, a penalty, or a modification based on a quality of a fit between the temporal measurements and the simulated temporal measurements; and updating the numerical model based on the reward, the penalty, or the modification.

Abstract: The purpose of the present invention is to provide an automatic analysis device capable of determining, through a simple processing, whether or not idle aspirate has occurred. The automatic analysis device according to the present invention determines whether or not idle aspirate has occurred, by calculating a parameter which specifies whether or not the length of a portion of a path through which the sample passes inside a dispensing probe is shorter than that during normal aspirate, the portion being actually filled with a sample (see FIG. 4).

Abstract: A plate changer includes a plate storage that includes therein a plate setting base, and is provided with a transport window for retrieving, in one direction in a horizontal plane, a sample plate set on the plate setting base; and a transport mechanism that has at least a pair of holding portions holding both side surfaces of a sample plate, and holds and transports the sample plate by the holding portions. The plate storage has a plate guide that supports a side surface of the sample plate set on the plate setting base and guides the sample plate to a predetermined setting position. When the holding portion is inserted into the plate storage from the transport window, the plate guide is configured to move to a position not interfering with the action of the holding portion.

Abstract: A reagent deposition area of a reagent dispensing system may include a dispersion bar located above a conveyor system, and a reagent module coupled to the dispersion bar. The reagent module may include at least one reagent dispensing device to dispense a number of reagents on a substrate carried on the conveyor system, and a module frame electrically and mechanically coupling the reagent dispensing device to the reagent dispensing system. The dispersion bar moves the reagent module in two coordinate directions planar with the surface of the substrate.

Abstract: A sample transfer device includes a sample container holder including at least one jet that ejects air, and the sample container holder holds an upper surface of a sample container in a non-contact state by a negative pressure generated due to horizontally outward flow of the air ejected from the jet.

Abstract: Various embodiments include a system having a pipetting chamber, a set of pipettor cartridges docked in the pipetting chamber, a gantry system mounted on a ceiling within the pipetting chamber, the gantry system including at least one stationary track aligned in a first direction, and a movable track aligned in a second direction distinct from the first direction, the movable track coupled to the at least one stationary track, and a carrier configured to transport each of the set of pipettor cartridges to a pipetting location within the pipetting chamber, the carrier configured to move each pipettor cartridge in a third direction perpendicular to both the first and second directions.

Abstract: An inventory management system for automatically generating a restocking order or prompting generation of a restocking order includes a storage space, a divider pivotable on the storage space between an upright position in which the divider separates the storage space into a front storage section and a rear storage section and a recumbent position that facilitates access to the rear storage section; and a motion detector module attached to the divider, the motion detector module including a sensor for detecting pivoting of the divider and a radio frequency transmitter in communication with the accelerometer and configured to emit radio frequency signals when the divider is rotated from the upright position to the recumbent position.

Abstract: The invention relates to fibre optic vibration and acceleration sensors comprising a dielectric mirror and a first light-guiding fibre connected to a coupler, the coupler being further connected via second light-guiding fibres to a light source and a detector that generates a voltage from incident light. Said sensors are characterised in particular by their simple implementation. For this purpose, a free end region of the first fibre is spaced apart from the dielectric mirror such that an edge of the dielectric mirror is located in the emergent light of the first fibre. In the unexcited state, the voltage of the detector generated from the light incident on the end of the first fibre is smaller than the voltage generated by the detector when the aperture cone of the first fibre is completely covered by the dielectric mirror and there is thus maximum reflection. Said voltage is a measure of the fibre optic vibration and acceleration sensor. A fibre is itself therefore used as a vibration-sensitive element.

Abstract: A method for closed loop operation of a capacitive accelerometer uses a single current source and a single current sink to apply an in-phase drive signal V1? to a first set of fixed capacitive electrode fingers and a corresponding anti-phase drive signal V2? to a second set of fixed capacitive electrode fingers. This provides a net electrostatic restoring force on the proof mass for balancing the inertial force of the applied acceleration and maintains the proof mass at a null position.

Abstract: A MEMS includes, in part, a parallel plate capacitor, a proofmass adapted to be displaced by a first distance from a rest state in response to a first voltage applied to the capacitor, and a piezoelectric material adapted to generate a second voltage in response to an external force applied to the MEMS. The second voltage causes the MEMS to transition from a standby mode to an active mode of operation. The proofmass is displaced by a second distance in response to the external force thereby causing the piezoelectric material to generate the second voltage. A spring couples the proofmass to the piezoelectric material, and a transistor turns on in response to the second voltage thereby causing the MEMS to transition to the active mode of operation. The proofmass returns to the rest state when the MEMS is in the active mode of operation.